文献速递神经介入CTDSA

CT高密度动脉征与急性卒中血管内取栓后阿替普酶疗效的关系

CT Hyperdense Artery Sign and the Effect of Alteplase in Endovascular Thrombectomy after Acute Stroke.
PubMed 文献 · Radiology · 2022-07-12

本研究为DIRECT-MT试验的二次分析,纳入633例急性大血管闭塞行血管内取栓的患者,评估基线非增强CT高密度动脉征(HAS)对阿替普酶联合取栓疗效的影响;结果显示HAS阳性患者联合阿替普酶预后更优(调整OR 1.82),而HAS阴性患者联合阿替普酶则预后更差(调整OR 0.62)。

要点

  • 基线非增强CT出现高密度动脉征(HAS)提示大血管闭塞,本组HAS阳性率为45%。
  • HAS阳性者联合阿替普酶取栓预后更优,调整OR 1.82(95%CI 1.18–2.79)。
  • HAS阴性者联合阿替普酶预后更差,调整OR 0.62(95%CI 0.42–0.91)。

核心结论

  • 急性缺血性卒中患者基线非增强CT存在HAS时,血管内取栓联合阿替普酶预后更好;而无HAS者联合阿替普酶预后更差。

研究设计与样本

  • DIRECT-MT前瞻性随机试验的二次分析,2018年2月至2019年7月纳入633例急性大血管闭塞患者,比较阿替普酶联合取栓与单纯取栓。

关键影像表现/征象

  • HAS由两名独立研究者于基线非增强CT上视觉判定。
  • 633例中283例(45%)存在HAS:单纯取栓组313例中142例(45%),联合阿替普酶组320例中141例(44%)。

诊断标准与关键数值

  • 主要结局为90天改良Rankin量表(mRS)评分,治疗与HAS交互作用P < .001。
  • HAS阳性者联合阿替普酶获更优结局的调整OR为1.82(95%CI 1.18, 2.79)。
  • HAS阴性者联合阿替普酶呈不良效应的调整OR为0.62(95%CI 0.42, 0.91)。
  • 次要结局中优结局(90天mRS 0–1分)P = .005、良好结局(90天mRS 0–2分)P = .008、最终成功再灌注P = .04。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

Background Recent evidence suggests that presence of an intracranial arterial thrombus with a hyperdense artery sign (HAS) at noncontrast CT (NCCT) is associated with better response to intravenous alteplase. Patients with HAS may benefit more from combined intravenous alteplase and endovascular treatment (EVT). Purpose To investigate whether HAS at NCCT modifies the treatment effect of adding intravenous alteplase on clinical outcome in patients with acute large-vessel occlusion undergoing EVT. Materials and Methods This study is a secondary analysis of a prospective randomized trial (Direct Intra-arterial thrombectomy in order to Revascularize AIS patients with large-vessel occlusion Efficiently in Chinese Tertiary hospitals: A Multicenter randomized clinical Trial [DIRECT-MT]), which compared adding alteplase to EVT versus EVT alone in participants with acute large-vessel occlusion between February 2018 and July 2019. Participants with catheter angiograms and adequate NCCT for HAS evaluation were included. HAS was determined visually by two independent investigators at baseline NCCT. Treatment effect of intravenous alteplase administration according to presence of HAS on the primary clinical outcome (modified Rankin Scale [mRS] score at 90 days) and secondary and safety outcomes were assessed using adjusted multivariable regression models. Results Among 633 included participants (356 men [56%]; median age, 69 years), HAS was observed in 283 participants (45%): 142 of 313 participants (45%) in the EVT-only group and 141 of 320 participants (44%) in the group with added intravenous alteplase. Treatment-by-HAS interaction was observed for the primary outcome (P < .001), whereby a shift in favor of better outcomes with added intravenous alteplase occurred in participants with HAS (adjusted odds ratio [OR]: 1.82; 95% CI: 1.18, 2.79), while an adverse effect was seen in participants without HAS (adjusted OR: 0.62; 95% CI: 0.42, 0.91). This also held true for three secondary outcomes (excellent outcome [mRS score of 0-1 at 90 days], P = .005; good outcome [mRS score of 0-2 at 90 days], P = .008; final successful reperfusion, P = .04) in the adjusted models. Conclusion After acute ischemic stroke, presence of hyperdense artery sign (HAS) at baseline noncontrast CT indicated better outcomes when alteplase was added to endovascular treatment, but adding alteplase to endovascular treatment resulted in worse outcomes in participants without HAS. Clinical trial registration no. NCT03469206 © RSNA, 2022 Online supplemental material is available for this article.

来源:Radiology,查看原文。版权归原作者所有。

引用

  1. Zhou, Jing, Ospel, et al. CT Hyperdense Artery Sign and the Effect of Alteplase in Endovascular Thrombectomy after Acute Stroke. Radiology. 2022. PMID: 35819327. doi:10.1148/radiol.212358

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。